Answers are grounded in this paper and cite their sources.
PACE-NODES is a phase III randomised controlled trial for patients with high risk localised prostate cancer, planned for radical radiotherapy with at least 12 months of androgen deprivation therapy, and suitable for stereotactic body radiotherapy (SBRT). Patients are randomised to receive either prostate SBRT (control) or prostate and pelvic nodal SBRT. In both arms, treatment is given in 5 fractions delivered on alternate days over 2 weeks. The aim of the trial is to determine whether prostate and pelvic nodal SBRT can improve outcomes for this patient group compared to prostate SBRT. Clinical trial registration: PACE NODES is registered on ClinicalTrials.gov (NCT05613023).
No takes yet. Share an insight, caveat, or question.
Pathmanathan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: